New combo aims to boost transplant success in aggressive blood cancers

NCT ID NCT04282187

Recruiting now Disease control Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 26 times

Summary

This study tests whether a combination of decitabine (a chemotherapy drug) and a JAK inhibitor (ruxolitinib, fedratinib, or pacritinib) can help prepare patients with advanced myeloproliferative neoplasms (blood cancers) for a stem cell transplant. About 25 adults will receive the drug combo before transplant to reduce cancer cells and improve transplant outcomes. The main goal is to see how many patients can successfully proceed to transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

ACUTE MYELOID LEUKEMIA ESSENTIAL THROMBOCYTHEMIA MYELODYSPLASTIC SYNDROME MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM MYELOPROLIFERATIVE NEOPLASM, NOT OTHERWISE SPECIFIED POLYCYTHEMIA VERA PRIMARY MYELOFIBROSIS SECONDARY MYELOFIBROSIS